Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy boosts standard treatment for advanced cervical cancer

NCT ID NCT04221945

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside their standard treatment. The goal was to see if the combination improves survival and delays cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,060 people

The number who actually took part.

Started

May 2020

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has high-risk locally advanced cervical cancer (LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage IB2-IIB (with node-positive disease) or FIGO 2014 Stages III-IVA * Has histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix * Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer, including investigational agents, and is immunotherapy-naïve * Female participants must not be pregnant or breastfeeding and agree to use highly effective contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab or placebo and 180 days following the end of chemoradiotherapy and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. * Female participants must abstain from breastfeeding during the study intervention period and for at least 120 days after the last dose of pembrolizumab or placebo and 180 days following the end of chemoradiotherapy * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment * Has provided a tissue sample from a core incisional or excisional biopsy of a tumor lesion * Has radiographically evaluable disease, either measurable or non-measurable per RECIST 1.1, as assessed by the local site investigator/radiology * Has adequate organ function within 7 days prior to the start of study treatment. Exclusion Criteria: * Has excluded subtypes of LACC * Has FIGO 2014 Stage IVB disease * Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy * Has bilateral hydronephrosis, unless at least one side has been stented or resolved by positioning of nephrostomy or considered mild and not clinically significant in the opinion of the investigator * Has anatomy or tumor geometry or any other reason or contraindication that cannot be treated with intracavitary brachytherapy or a combination of intracavitary and interstitial brachytherapy * Has received a live vaccine within 30 days prior to the first dose of study treatment * Has received treatment with systemic immunostimulatory agents, colony stimulating factors, interferons, interleukins and vaccine combinations within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1 * Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137) * Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization * Has any contraindication to the use of cisplatin * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years * Has severe hypersensitivity to pembrolizumab and/or any of its excipients * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy * Has a known history of Human Immunodeficiency Virus (HIV) infection * Has a known history of Hepatitis B or known active Hepatitis C virus infection * Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results, and in the judgment of the investigator or Sponsor, would make the participant inappropriate for entry into this study * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study * Has had an allogenic tissue/solid organ transplant * Has evidence of metastatic disease per RECIST 1.1 including lymph nodes above the first lumbar vertebra (L1) cephalad body, in the inguinal region

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 cervical cancer Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uterine cervical neoplasms

Contacts and locations

Locations

  • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0541)

    Bologna, 40138, Italy

  • A.O.U. Citta della Salute e della Scienza di Torino ( Site 0535)

    Torino, 10126, Italy

  • AZ St Lucas ( Site 0349)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Acibadem Adana Hastanesi ( Site 0756)

    Adana, 01130, Turkey (Türkiye)

  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 0009)

    Orlando, Florida, 32804, United States

  • Affiliated Cancer Hospital of Guangxi Medical University ( Site 1036)

    Nanning, Guangxi, 530021, China

  • Aichi Cancer Center Hospital ( Site 1155)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Alexandra General Hospital ( Site 0477)

    Athens, Attica, 11528, Greece

  • Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030)

    Pittsburgh, Pennsylvania, 15244, United States

  • Anhui Provincial Cancer Hospital ( Site 1007)

    Hefei, Anhui, 230031, China

  • Anhui Provincial Hospital ( Site 1029)

    Hefei, Anhui, 230001, China

  • Asan Medical Center ( Site 1062)

    Seoul, Seoul, 05505, South Korea

  • Baskent Universitesi Ankara Hastanesi ( Site 0754)

    Ankara, 06490, Turkey (Türkiye)

  • C.I.U. Hopital Ambroise Pare ( Site 0353)

    Mons, Hainaut, 7000, Belgium

  • CHU Jean Minjoz ( Site 0411)

    Besançon, Doubs, 25000, France

  • Centre Hospitalier Lyon Sud ( Site 0413)

    Pierre-Bénite, Rhone, 69310, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0101)

    Montreal, Quebec, H2X 0A9, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0

    Québec, Quebec, G1J 1Z4, Canada

  • Centro Investigación del Cáncer James Lind ( Site 0194)

    Temuco, Araucania, 4800827, Chile

  • Centro Medico Imbanaco de Cali S.A ( Site 0227)

    Cali, Valle del Cauca Department, 760042, Colombia

  • Centro Medico Integral De Cancerología (CEMIC) ( Site 0322)

    Quetzaltenango, 09002, Guatemala

  • Centro Medico Monte Carmelo ( Site 0289)

    Arequipa, Ariqipa, 04001, Peru

  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0321)

    Guatemala City, 01010, Guatemala

  • Chaim Sheba Medical Center ( Site 0814)

    Ramat Gan, 5262000, Israel

  • Charite Universitaetsmedizin Berlin ( Site 0442)

    Berlin, 13353, Germany

  • Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 0741)

    Chelyabinsk, Chelyabinsk Oblast, 454087, Russia

  • Chongqing Cancer Hospital ( Site 1030)

    Chongqing, Chongqing Municipality, 400030, China

  • Clinica San Gabriel ( Site 0296)

    San Miguel, Lima region, 15087, Peru

  • Complejo Hospitalario de Jaen ( Site 0632)

    Jaén, 23007, Spain

  • Cork University Hospital ( Site 0504)

    Cork, T12 DC4A, Ireland

  • Debreceni Egyetem Klinikai Kozpont ( Site 0845)

    Debrecen, 4032, Hungary

  • Ehime University Hospital ( Site 1157)

    Tōon, Ehime, 790-0295, Japan

  • Euromedica General Clinic of Thessaloniki ( Site 0474)

    Thessaloniki, 546 45, Greece

  • Fakultni Nemocnice Brno Bohunice ( Site 0912)

    Brno, Brno-mesto, 602 00, Czechia

  • Fakultni nemocnice Kralovske Vinohrady ( Site 0913)

    Prague, 100 34, Czechia

  • Fakultni nemocnice Ostrava ( Site 0909)

    Ostrava, Moravian-Silesian Region, 708 52, Czechia

  • Fondazione Giovanni Pascale Di Napoli ( Site 0544)

    Naples, 80131, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0542)

    Milan, 20133, Italy

  • Fundacion Centro de Investigacion Clinica CIC ( Site 0231)

    Medellín, Antioquia, 050021, Colombia

  • Fundacion Valle del Lili ( Site 0230)

    Cali, Valle del Cauca Department, 760032, Colombia

  • GBUZ SPb CRPCstmc(o) ( Site 0746)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • GZA Sint Augustinus ( Site 0356)

    Wilrijk, Antwerpen, 2610, Belgium

  • General Hospital of Patras. St Andrews ( Site 0473)

    Pátrai, Achaia, 262 00, Greece

  • Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0876)

    Kharkiv, Kharkiv Oblast, 61024, Ukraine

  • Grupo Angeles SA ( Site 0319)

    Guatemala City, 01015, Guatemala

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 0638)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hadassah Medical Center. Ein Kerem ( Site 0816)

    Jerusalem, 9112001, Israel

  • Harbin Medical University Cancer Hospital ( Site 1013)

    Harbin, Heilongjiang, 150081, China

  • Helse Bergen HF Haukeland Universitetssjukehus ( Site 0601)

    Bergen, Hordaland, 5021, Norway

  • Hoag Memorial Hospital Presbyterian ( Site 0038)

    Newport Beach, California, 92663, United States

  • Hokkaido University Hospital ( Site 1163)

    Sapporo, Hokkaido, 060-8648, Japan

  • Hollings Cancer Center ( Site 0007)

    Charleston, South Carolina, 29425, United States

  • HonorHealth Research Institute - Biltmore ( Site 8009)

    Phoenix, Arizona, 85016, United States

  • Hosp Clin Univ de Santiago ( Site 0629)

    Santiago de Compostela, La Coruna, 15706, Spain

  • Hospital Clinico Universitario Lozano Blesa ( Site 0630)

    Zaragoza, 50009, Spain

  • Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0637)

    Badalona, Barcelona, 08916, Spain

  • Hospital Hygeia ( Site 0478)

    Athens, Attica, 151 23, Greece

  • Hospital Nacional Arzobispo Loayza ( Site 0292)

    Lima, 15082, Peru

  • Hospital Nacional Daniel Alcides Carrion ( Site 0293)

    Callao, Lima, 07021, Peru

  • Hospital Nacional Guillermo Almenara Irigoyen ( Site 0291)

    Lima, 15082, Peru

  • Hospital Universitari Vall d Hebron ( Site 0634)

    Barcelona, 08035, Spain

  • Hospital das Clinicas da UFMG ( Site 0172)

    Belo Horizonte, Minas Gerais, 30130-100, Brazil

  • Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 0287)

    Trujillo, La Libertad, 13013, Peru

  • Hospital de Clínicas de Ribeirão Preto ( Site 0171)

    Ribeirão Preto, São Paulo, 14048900, Brazil

  • Hunan Cancer Hospital ( Site 1015)

    Changsha, Hunan, 233004, China

  • I.U. Cerrahpasa Medical Faculty ( Site 0755)

    Istanbul, Istanbul, 34093, Turkey (Türkiye)

  • IRCCS Ospedale San Raffaele ( Site 0539)

    Milan, 20132, Italy

  • Institut Claudius Regaud ( Site 0417)

    Toulouse, Haute-Garonne, 31059, France

  • Instituto Nacional Do Cancer II ( Site 0173)

    Rio de Janeiro, 20220-410, Brazil

  • Instituto Nacional de Cancerologia E.S.E ( Site 0228)

    Bogotá, Bogota D.C., 110321, Colombia

  • Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 0290)

    Lima, 15036, Peru

  • Iram Cancer Research ( Site 0198)

    Santiago, Region M. de Santiago, 7630370, Chile

  • Istituto Europeo di Oncologia ( Site 0536)

    Milan, Milano, 20141, Italy

  • Istituto Nazionale Tumori Regina Elena ( Site 0540)

    Rome, Roma, 00144, Italy

  • Istituto di Candiolo - IRCCS ( Site 0546)

    Candiolo, Piedmont, 10060, Italy

  • Iwate Medical University Hospital ( Site 1165)

    Shiwa-gun, Iwate, 028-3695, Japan

  • Japanese Foundation for Cancer Research-Gynecologic Oncology ( Site 1171)

    Tokyo, 135-8550, Japan

  • Kagoshima City Hospital ( Site 1166)

    Kagoshima, 890-8760, Japan

  • Karmanos Cancer Institute ( Site 0018)

    Detroit, Michigan, 48201, United States

  • Karolinska Universitetssjukhuset ( Site 0784)

    Stockholm, Stockholm County, 171 76, Sweden

  • Keimyung University Dongsan Medical Center ( Site 1066)

    Daegu, Taegu-Kwangyokshi, 42601, South Korea

  • Keio University Hospital ( Site 1170)

    Tokyo, 160-8582, Japan

  • Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0453)

    Munich, Bavaria, 81675, Germany

  • Klinikum der Universitaet in Muenchen ( Site 0446)

    Munich, Bavaria, 80336, Germany

  • Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0729)

    Krasnoyarsk, Krasnoyarsk Krai, 660133, Russia

  • Kurume University Hospital ( Site 1164)

    Kurume, Fukuoka, 830-0011, Japan

  • Kyorin University Hospital ( Site 1158)

    Mitaka, Tokyo, 181-8611, Japan

  • Legacy Good Samaritan Medical Center ( Site 0013)

    Portland, Oregon, 97210, United States

  • Liga Norte Riograndense Contra o Cancer ( Site 0170)

    Natal, Rio Grande do Norte, 59075-740, Brazil

  • Linkou Chang Gung Memorial Hospital ( Site 1097)

    Taoyuan, 333, Taiwan

  • Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0882)

    Lviv, Lviv Oblast, 79031, Ukraine

  • MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 0722)

    Moscow, Moscow, 125284, Russia

  • Mackay Memorial Hospital ( Site 1094)

    Taipei, 104, Taiwan

  • Maharaj Nakorn Chiang Mai Hospital ( Site 1133)

    Chiang Mai, 50200, Thailand

  • McGill University Health Centre ( Site 0105)

    Montreal, Quebec, H4A 3J1, Canada

  • Medi-K Cayala ( Site 0318)

    Guatemala City, 01016, Guatemala

  • Medizinische Universitat Graz ( Site 0569)

    Graz, Styria, 8036, Austria

  • Medizinische Universitat Innsbruck ( Site 0566)

    Innsbruck, Tyrol, 6020, Austria

  • Medizinische Universität Wien ( Site 0567)

    Vienna, State of Vienna, 1090, Austria

  • Minnesota Oncology Hematology, PA ( Site 8007)

    Minneapolis, Minnesota, 55404, United States

  • Monash Health-Monash Medical Centre ( Site 0970)

    Clayton, Victoria, 3168, Australia

  • National Cancer Center ( Site 1065)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital ( Site 1172)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 1159)

    Kashiwa, Chiba, 2778577, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 1167)

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 1162)

    Matsuyama, Ehime, 791-0280, Japan

  • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 0725)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • National Taiwan University Hospital ( Site 1095)

    Taipei, 100, Taiwan

  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0166)

    São Paulo, São Paulo, 04014-002, Brazil

  • OLV Ziekenhuis ( Site 0352)

    Aalst, Oost-Vlaanderen, 9300, Belgium

  • Oncocentro ( Site 0195)

    Viña del Mar, Valparaiso, Chile

  • Oncologika S.A. ( Site 0323)

    Guatemala City, 01010, Guatemala

  • Oncomedica ( Site 0320)

    Guatemala City, 01010, Guatemala

  • Orszagos Onkologiai Intezet ( Site 0846)

    Budapest, 1122, Hungary

  • Osaka International Cancer Institute ( Site 1161)

    Osaka, 541-8567, Japan

  • Oslo Universitetssykehus Radiumhospitalet ( Site 0600)

    Oslo, 0379, Norway

  • Ospedale Vito Fazzi ( Site 0547)

    Lecce, 73100, Italy

  • Our Lady of the Lake Regional Medical Center. ( Site 0031)

    Baton Rouge, Louisiana, 70817, United States

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0026)

    Fort Wayne, Indiana, 46845, United States

  • Peking Union Medical College Hospital ( Site 1001)

    Beijing, Beijing Municipality, 100730, China

  • Peter MacCallum Cancer Centre ( Site 0971)

    Melbourne, Victoria, 3000, Australia

  • Policlinico Universitario Gemelli ( Site 0538)

    Roma, 00168, Italy

  • Princess Margaret Cancer Centre ( Site 0102)

    Toronto, Ontario, M5G 2M9, Canada

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0701)

    London, London, City of, SW3 6JJ, United Kingdom

  • Ramathibodi Hospital, Mahidol University ( Site 1131)

    Rajthevee, Bangkok, 10400, Thailand

  • Rambam Medical Center ( Site 0815)

    Haifa, 3109601, Israel

  • Royal Brisbane and Women s Hospital ( Site 0972)

    Herston, Queensland, 4029, Australia

  • Royal Devon and Exeter Foundation Trust Hospital ( Site 0699)

    Exeter, England, United Kingdom

  • Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 0696)

    London, Surrey, SM3 5PT, United Kingdom

  • Saitama Cancer Center ( Site 1169)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Saitama Medical University International Medical Center ( Site 1168)

    Hidaka, Saitama, 350-1298, Japan

  • Samsung Medical Center ( Site 1064)

    Seoul, 06351, South Korea

  • Sanford Bismarck Medical Center ( Site 0046)

    Bismarck, North Dakota, 58501, United States

  • Sanford Gynecology Oncology ( Site 0003)

    Sioux Falls, South Dakota, 57104, United States

  • Severance Hospital ( Site 1063)

    Seoul, 03722, South Korea

  • Shanghai Cancer Hospital ( Site 1000)

    Shanghai, Shanghai Municipality, 200032, China

  • Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 1039)

    Shanghai, Shanghai Municipality, 201204, China

  • Sichuan Cancer Hospital ( Site 1018)

    Chengdu, Sichuan, 610041, China

  • Smilow Cancer Center at Yale-New Haven ( Site 0023)

    New Haven, Connecticut, 06510, United States

  • Sociedad Oncovida S.A. ( Site 0196)

    Santiago, Region M. de Santiago, 7510032, Chile

  • Songklanagarind Hospital ( Site 1130)

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Sourasky Medical Center ( Site 0819)

    Tel Aviv, 6423906, Israel

  • Srinagarind Hospital. Khon Kaen University ( Site 1132)

    Mueang, Changwat Khon Kaen, 40002, Thailand

  • St James Hospital ( Site 0505)

    Dublin, D8, Ireland

  • St John of God Subiaco Hospital ( Site 0969)

    Subiaco, Western Australia, 6008, Australia

  • Texas Oncology-Austin Central ( Site 8006)

    Austin, Texas, 78731, United States

  • Texas Oncology-Fort Worth Cancer Center ( Site 8001)

    Fort Worth, Texas, 76104, United States

  • Texas Oncology-San Antonio Medical Center ( Site 8002)

    San Antonio, Texas, 78240, United States

  • Texas Oncology-The Woodlands ( Site 8003)

    The Woodlands, Texas, 77380, United States

  • The First Affiliated Hospital of Xiamen University ( Site 1025)

    Xiamen, Fujian, 361003, China

  • The First Affiliated Hospital of Xinjiang Medical University ( Site 1012)

    Ürümqi, Xinjiang, 830054, China

  • The First Affiliated Hospital.Sun Yat-sen University ( Site 1005)

    Guangzhou, Guangdong, 510080, China

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio, 43210, United States

  • UC Davis Comprehensive Cancer Center ( Site 0017)

    Sacramento, California, 95817, United States

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027)

    Los Angeles, California, 90095, United States

  • UVA Health System ( Site 0005)

    Charlottesville, Virginia, 22908, United States

  • UZ Leuven ( Site 0354)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • UZA University Hospital Antwerp ( Site 0351)

    Edegem, Antwerpen, 2650, Belgium

  • Universitaetsklinik Leipzig ( Site 0456)

    Leipzig, Saxony, 04103, Germany

  • Universitaetsklinikum Carl Gustav Carus der Technischen Univ ( Site 0452)

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Freiburg ( Site 0454)

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0445)

    Hamburg, 20246, Germany

  • University of Colorado Health Sciences Center and Hospital ( Site 0028)

    Denver, Colorado, 80262, United States

  • University of Kentucky Markey Cancer Center ( Site 0015)

    Lexington, Kentucky, 40536, United States

  • University of New Mexico Comprehensive Cancer Center-Clinical Research Office ( Site 0019)

    Albuquerque, New Mexico, 87106, United States

  • University of North Carolina at Chapel Hill ( Site 0025)

    Chapel Hill, North Carolina, 27514, United States

  • University of the Ryukyus Hospital ( Site 1156)

    Nakagami-gun, Okinawa, 903-0215, Japan

  • Universitätsmedizin Mannheim-Department of Obstetrics and Gynecology ( Site 0443)

    Mannheim, Baden-Wurttemberg, 68167, Germany

  • Virginia Commonwealth University ( Site 0024)

    Richmond, Virginia, 23219, United States

  • Westmead Hospital ( Site 0973)

    Westmead, New South Wales, 2145, Australia

  • Willamette Valley Cancer Institute and Research Center ( Site 8000)

    Eugene, Oregon, 97401, United States

  • Women's Cancer Care ( Site 0039)

    Covington, Louisiana, 70433, United States

  • Xiangya Hospital Central-South University ( Site 1009)

    Changsha, Hunan, 410008, China

  • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0734)

    Yaroslavl, Yaroslavl Oblast, 150054, Russia

  • Zhejiang Cancer Hospital ( Site 1004)

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang Provincial People's Hospital ( Site 1021)

    Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.